GSK Reveals Positive Early Data For Ris-Rez In Extensive-stage Small Cell Lung Cancer

GSK's risvutatug showed a 61% response rate at 8 mg/kg vs 32% at 6 mg/kg in a phase Ib SCLC trial. Adverse events were 42% at 8 mg/kg and 15% at 6 mg/kg. Full data is expected at ESMO 2026. GSK states the results support continued development.

GSK reported positive results from a drug trial for small cell lung cancer, with an 8mg/kg dose showing a 61% objective response rate. LondonMetric reported an 8% increase in net rental income to GBP240 million for the first half. Volex expects record half-year revenue of at least USD710 million, up 22% year-over-year, and annual profit at the upper end of market forecasts. ITM Power narrowed its annual loss to GBP24.8 million, with revenue up 68% to GBP43.6 million.

GSK's experimental lung cancer drug, Ris-Rez, showed a 61% response rate in a small global trial, with higher doses causing more severe side effects. The drug is being tested in patients with extensive-stage small cell lung cancer who had relapsed after previous treatments. GSK plans to present the findings at the European Society for Medical Oncology Congress 2026.

GSK (LSE/NYSE:GSK) reported positive phase 1b trial data for risvutatug rezetecan, a lung cancer drug candidate, showing a 61% response rate at 8 mg/kg dose. The trial involved 50 patients with relapsed extensive-stage small cell lung cancer. GSK plans to proceed with a global phase III study using the 8 mg/kg dose. The company acquired rights to the drug from Hansoh Pharma, excluding certain regions.

GSK PLC reported that its experimental lung cancer drug, risvutatug rezetecan, showed a 61% response rate in an early-stage global trial at the higher dose tested. The company is using the higher dose in its ongoing phase III study and has seen manageable safety profiles. GSK acquired rights to the drug outside certain regions and is evaluating it for multiple cancer indications.

GSK reported positive early data for its investigational drug Ris-Rez in extensive-stage small cell lung cancer, showing a 61% overall response rate in a phase Ib trial. The results support accelerated development, including an ongoing global phase III trial. GSK aims to advance targeted medicines for cancers with high unmet needs.